ClinicalTrials.gg
Active, not recruitingNCT05317416MagnetisMM-7Updated Apr 16, 2026

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

A Phase 3 interventional study of Elranatamab and Lenalidomide in Multiple Myeloma, sponsored by Pfizer. Active, not recruiting at 209 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
854
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Enrollment
3rd of 31
854 · median 75
Started
2022
with 1 other
Phase 3
5 of 31
4 open now
Primary completion
2027-08
later than 8 of 24 live
Registered
8th of 31
by date
Lead sponsor
13 of 31
Pfizer

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 3, reaches primary completion later than 8 of the 24 other live ones, and was the 8th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years

Read the detailed description

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • BCMA
  • Multiple Myeloma
  • Newly diagnosed
  • Elranatamab
  • Targeted T-cell
  • MagnetisMM
  • MM7
  • Phase 3
  • B-cell Maturation Antigen
  • monoclonal antibody
  • Stem cell transplant
  • Autologous stem cell transplant (ASCT)
  • Hematologic disease
  • Minimum residual disease
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with at diagnosis
  • Part 1 patients must be MRD positive, Part 2 patients can be MRD negative or MRD positive
  • History of induction therapy for newly diagnosed MM, followed by high dose therapy and stem cell transplant. Randomization must occur within 120 days from the stem cell transplant. For participants who receive consolidation therapy after ASCT, randomization must occur within 60 days of consolidation and within 7 months from ASCT.
  • Partial Response or better according to IMWG criteria at the time of randomization
  • Must have an archival bone marrow aspirate sample(s) to identify the dominant malignant (index) clone by central laboratory NGS test (ClonoSEQ assay) that is used to track MRD status. This sample should preferably be collected before induction treatment (eg, at diagnosis) or before transplant.
  • performance status ≤1
  • Resolved acute effects of any prior therapy to baseline severity or Grade ≤ 1
  • Not pregnant and willing to use

Exclusion criteria

Exclusion Criteria:

  • Plasma cell leukemia
  • Amyloidosis, Waldenström's macroglobulinemia
  • POEMS syndrome
  • Known active CNS involvement or clinical signs of myelomatous meningeal involvement
  • Previous MM maintenance treatment
  • Prior treatment with BCMA targeted therapy
  • Any other active within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
  • Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) , , and known or AIDS-related illness
  • Previous administration with an drug or vaccine within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
854 participants (actual)

Study arms

  • Experimental
    Arm A - Part 1

    Elranatamab

    Drug: Elranatamab

  • Active comparator
    Arm B - Part 1

    Lenalidomide

    Drug: Lenalidomide

  • Active comparator
    Arm B - Part 2

    Lenalidomide

    Drug: Lenalidomide

  • Experimental
    Arm C - Part 2

    Elranatamab

    Drug: Elranatamab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria

    Time frame: Assessed for up to approximately 5 years

Secondary outcomes

  1. Minimal residual disease Negative rate

    per IMWG as assessed via next generation sequencing (NGS)

    Time frame: 12 months after randomization

  2. Progression Free Survival by BICR per IMWG in IMWG 2025 high-risk participants

    Progression Free Survival by BICR per IMWG in IMWG 2025 high-risk participants

    Time frame: Assessed up to approximately 5 years

  3. PFS by BICR per IMWG in IMWG 2025 standard-risk participant

    PFS by BICR per IMWG in IMWG 2025 standard-risk participant

    Time frame: Assessed up to approximately 5 years

  4. Overall Survival

    Defined as the time from randomization until death due to any cause

    Time frame: Assessed for up to approximately 5 years

  5. MRD-negative rate per IMWG 2025

    Assessed via NGS in IMWG 2025 subgroups

    Time frame: 12 months after randomization

  6. Sustained MRD negative rate

    Sustained Minimal Residual Disease negative rate per IMWG criteria as assessed via Next Generation Sequencing

    Time frame: 24 months after randomization

  7. Progression Free Survival

    Progression Free Survival by investigator per IMWG response criteria

    Time frame: Assessed for up to approximately 5 years

  8. Overall minimal residual disease negative rate

    Minimal residual disease negative rate per IMWG criteria

    Time frame: Assessed for up to approximately 5 years

  9. Duration of minimal residual disease negativity

    Minimal residual disease negativity per IMWG criteria

    Time frame: Assessed for up to approximately 5 years

  10. Sustained minimal residual disease negativity rate

    Minimal residual disease negativity per IMWG criteria that has lasted a minimum of 12 months

    Time frame: Assessed for up to approximately 5 years

  11. Complete response rate

    Complete response rate by blinded independent central review and by investigator per IMWG criteria

    Time frame: Assessed for up to approximately 5 years

  12. Duration of complete response

    Duration of complete response by blinded independent central review and by investigator per IMWG criteria

    Time frame: Assessed for up to approximately 5 years

  13. Progression Free Survival 2

    Progression Free Survival to the date of second objective disease progression by investigator per IMWG response criteria

    Time frame: Assessed for up to approximately 5 years

  14. Frequency of adverse events

    Adverse event as characterized by type, frequency, severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5, seriousness and relationship to the study intervention

    Time frame: Up to 90 days after last dose

  15. Severity of Cytokine Release Syndrome and Immune effector Cell Associated Neurotoxicity syndrome

    Cytokine Release Syndrome and Immune effector Cell Associated Neurotoxicity syndrome severity assessed per ASH-ASTCT criteria

    Time frame: Assessed for up to approximately 5 years

  16. Pre-dose concentrations of elranatamab

    Pharmacokinetics of elranatamab (trough concentrations of elranatamab)

    Time frame: Assessed for up to approximately 5 years

  17. Post-dose concentrations of elranatamab

    Pharmacokinetics of elranatamab (Post-dose serum concentrations of elranatamab)"

    Time frame: Assessed for up to approximately 5 years

  18. Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab

    Immunogenicity of elranatamab

    Time frame: Assessed for up to approximately 5 years

  19. Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30

    Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms

    Time frame: Assessed for up to approximately 5 years

  20. Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20

    Higher scores on the functioning subscales (body image, future perspective) represent higher levels of functioning, whereas higher scores on the symptom subscales (disease symptoms, side effects) represent a greater presence of symptoms

    Time frame: Assessed for up to approximately 5 years

07

Study locations

209 sites

Showing the first 100 of 209 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 64 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 64 months is above that.

Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2022
First posted
Apr 7, 2022
StartActual
Mar 25, 2022
Primary completionEst.
Aug 4, 2027
CompletionEst.
Oct 31, 2029
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05317416
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
Mar 25, 2022
Primary completion
Aug 4, 2027 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Apr 16, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elranatamab

Start the discussion